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Introduction
When managing chronic diseases, understanding the patients’ perspective in terms of
expectations, concerns, and beliefs about their disease could result in better patient–
physician communications and consequently improve management of the disease.1
Personality traits and health care beliefs are likely to affect patient perceptions of
care and could in turn influence the understanding between patients and physicians.
These types of patient traits have been defined as “patient’s engagement” and can be
quantified using survey instruments, such as the Patient Activation Measure (PAM).2
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Background and aims: We used data from the Continuing to Confront COPD International
Patient Survey to test the hypothesis that patients with COPD who report less engagement with
their disease management are also more likely to report greater impact of the disease.
Methods: This was a population-based, cross-sectional survey of 4,343 subjects aged $40 years
from 12 countries, fulfilling a case definition of COPD based on self-reported physician diagnosis
or symptomatology. The impact of COPD was measured with COPD Assessment Test, modified
Medical Research Council Dyspnea Scale, and hospital admissions and emergency department
visits for COPD in the prior year. The 13-item Patient Activation Measure (PAM-13) instrument
and the 8-item Morisky Medication Adherence Scale (MMAS-8) were used to measure patient
disease engagement and medication adherence, respectively.
Results: Twenty-eight percent of subjects reported being either disengaged or struggling
with their disease (low engagement: PAM-13 levels 1 and 2), and 35% reported poor adherence (MMAS-8 ,6). In univariate analyses, lower PAM-13 and MMAS-8 scores were
significantly associated with poorer COPD-specific health status, greater breathlessness and
lower BMI (PAM-13 only), less satisfaction with their doctor’s management of COPD, and
more emergency department visits. In multivariate regression models, poor satisfaction with
their doctor’s management of COPD was significantly associated with both low PAM-13
and MMAS-8 scores; low PAM-13 scores were additionally independently associated with
higher COPD Assessment Test and modified Medical Research Council scores and low BMI
(underweight).
Conclusion: Poor patient engagement and medication adherence are frequent and associated
with worse COPD-specific health status, higher health care utilization, and lower satisfaction
with health care providers. More research will be needed to better understand what factors can
be modified to improve medication adherence and patient engagement.
Keywords: chronic obstructive pulmonary disease, patient survey, patient engagement,
adherence
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Studies in patients with chronic conditions have shown that
greater engagement (higher PAM score) is associated with
an improvement in patient health-related behaviors.3,4 These
data suggest that patients who are better engaged with their
disease by actively participating in their own care are more
likely to have better health outcomes. For example, programs
that promote self-management or patient-centered chronic
care initiatives in COPD have been shown to reduce health
care resource utilization, including COPD-related hospital
admissions.5,6
Patient engagement with their disease can also be
reflected in reported or measured adherence to prescribed
medication. Good adherence to prescribed COPD medication
has been associated with reduced all-cause mortality and
hospital admissions due to COPD exacerbations.7,8 However,
adherence among COPD patients is often poor.9–13
We hypothesized that COPD patients who report lower
levels of engagement or medication adherence would report
a greater burden of COPD in terms of humanistic impact
(health status), symptom control, and health care utilization
than patients who report greater engagement or adherence.
Further, we aimed to identify factors associated with patients’
level of engagement with COPD and adherence with COPD
treatment.

Methods
Study design
The study objectives that were explored in the Continuing
to Confront COPD International Patient Survey, have been
described previously;14 a detailed description of the survey
sampling methods can be found in the online appendix. This
was a population-based survey of 4,343 adults who fulfilled
a case definition of COPD defined as adults aged 40 years
and older who reported 1) a physician diagnosis of COPD/
emphysema, 2) a physician diagnosis of chronic bronchitis, or
3) met a symptom-based definition of chronic bronchitis and
were either taking respiratory medication for their condition
or had chronic cough with phlegm most days. A history of
smoking was not required as part of the case definition for
this study. The survey was conducted in 12 countries; Brazil,
France, Germany, Italy, Japan, Mexico, the Netherlands,
Russia, South Korea, Spain, the UK, and the US.
Participation in the survey was entirely voluntary and
confidential, and all subject data were anonymous. The
survey protocol and consent procedure were reviewed by
the Abt SRBI Institutional Review Board (registered with
the Office for Protection from Research Risks, Health and
Human Services) and granted an Institutional Review Board

882

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

exemption as the criteria for exemption under 45 CFR
46.101(b) (2) of the United States Code of Federal Regulations were met. In countries where face-to-face interviews
were conducted in the respondents’ home, modest incentives
may have been offered, the value of which was less than
US$6 (eg, mobile phone top-up card, tea, chocolates). In
Japan, the members of the online panel were compensated
by the panel provider directly, typically $11. No other incentives were provided.
Patients completed a structured questionnaire about their
COPD disease severity, respiratory symptoms, treatment for
COPD, health care resource use for exacerbations of COPD
in the prior 12 months (number of emergency department
visits and number of hospitalizations), smoking history and
toxic exposures, and overall satisfaction with their doctor’s
management and treatment of COPD. Symptom severity
was assessed using the modified Medical Research Council
(mMRC) Dyspnea Scale,15 and health status with the COPD
Assessment Test (CAT).16,17 The primary hypotheses were
addressed using the PAM-13,2 and Morisky Medication
Adherence Scale (MMAS)-8.18 Validated translations of
the patient reported outcome instruments were used and
permission for their use was obtained.

Patient Activation Measure-13
The PAM-13 was used to measure patients’ self-confidence
in their role in managing their disease and assertiveness in
dealing with the health care systems.2 This scale evaluates
patients’ responsibility, attitude, confidence, knowledge, and
understanding of their disease.
PAM-13 yields a scaled score ranging from 0 to 100 that
assigns a patient to one of four levels:
• Level 1 (PAM-13 score of 47.0 or lower): disengaged
and overwhelmed
• Level 2 (PAM-13 score of 47.1 to 55.1): becoming
aware but still struggling
• Level 3 (PAM-13 score of 55.2 to 67.0): taking action
• Level 4 (PAM-13 score of 67.1 or above): maintaining
behaviors and pushing further.

Morisky Medication Adherence Scale-8
The MMAS-8 is an 8-item, self-reported measure of
adherence in recent users of medication (recall period is
14 days).18
Each question is given either a dichotomous or Likert
scale-type response resulting in an overall score which
ranges from 1 to 8, with higher scores indicating greater
adherence. Adherence is classified as low (score 1–5),
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medium (score 6–7), or high (score 8) according to the
overall score.

Statistical analyses
Analyses related to patient engagement were conducted in
4,339 respondents. Analysis of patient adherence was limited to 3,135 respondents who reported taking medication
in the past 14 days and thus were eligible to complete
MMAS-8.
All analyses were weighted using a summary survey
weight variable to address factors of age and sex sampling
specific to each country and also to adjust for the proportion of each country’s contribution to the study population.
Therefore, all percentages presented in the paper are
weighted percentages. Differences in demographic,
clinical, and behavioral traits across levels of PAM-13
and MMAS-8 were tested using weighted chi-square test
for categorical variables and proportional odds model for
continuous variables. Weighted logistic regression multivariate models (PROC SURVEYLOGISTICS) were used
to determine factors associated with (a) poor adherence
(MMAS-8 score ,6) and (b) poor patient engagement

(PAM-13 levels 1 and 2) using characteristics showing
a significant univariate relationship with each respective
outcome and country. All analyses were conducted in
SAS v9.3.

Results
In the population of 4,343 respondents who fulfilled the
survey definition of COPD, the mean age was 60.7 years
(standard deviation 12.1 years), 48% were male, and 64%
were current or former smokers.14 Distribution of traits in the
subsample not completing the MMAS-8 was mostly identical
or differed nonsignificantly (data not shown).

Patient engagement with COPD
management and its determinants
The majority of respondents with valid PAM-13 scores
(N=4,339) indicated high PAM-13 scores with 51% scoring
at the highest Level 4 and 22% at Level 3 (Table 1). However,
15% of respondents were disengaged and overwhelmed by
their disease (Level 1) and 13% described themselves as struggling with their disease (Level 2). Weighted mean value for
the PAM-13 score was 66.75 (standard deviation 17.90).

Table 1 Characteristics of respondents with COPD according to activation level as measured with Patient Activation Measure (PAM)-13
Characteristic^

Females
Males
Age (years)
40–59
60+
Smoking status
Never smoker
Former smoker
Current smoker
BMI (kg/m2), mean (SD)
CAT score, weighted mean (SD)
CAT impact category
Low impact (1–10)
Medium impact (11–20)
High impact (21–30)
Very high impact (31–40)
mMRC Dyspnea score
0–1
2–4
Self-reported history of past
spirometry
Yes
No

PAM-13 level

P-value across
PAM-13
levels¥

Level 1: disengaged
and overwhelmed
N=639 (15%)

Level 2:
becoming aware
N=561 (13%)

Level 3:
taking action
N=946 (22%)

Level 4: maintaining
behaviors
N=2,193 (51%)

49.4
50.6

51.2
48.8

48.6
51.4

54.6
45.4

0.010

45.2
54.8

51.6
48.4

49.5
50.5

48.1
51.9

0.653

38.4
31.4
30.2
26.2 (5.9)
23.7 (8.8)

42.5
35.0
22.6
26.0 (6.2)
21.3 (9.7)

35.5
36.9
27.6
26.4 (6.0)
20.3 (8.9)

33.3
38.8
27.9
27.6 (6.6)
21.3 (9.3)

0.030

9.1
23.5
43.7
23.7

16.6
27.8
35.4
20.1

16.7
31.9
39.1
12.3

14.7
29.9
37.6
17.8

,0.0001

44.0
56.0

53.9
46.1

59.4
40.6

52.3
47.7

,0.01

70.2
29.8

71.4
28.6

74.8
25.2

81.4
18.6

,0.0001

,0.0001
,0.001

(Continued)

International Journal of COPD 2016:11

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

883

Dovepress

Müllerová et al

Table 1 (Continued)

International Journal of Chronic Obstructive Pulmonary Disease downloaded from https://www.dovepress.com/ by 128.163.8.74 on 18-Oct-2017
For personal use only.

Characteristic^

P-value across
PAM-13
levels¥

Level 1: disengaged
and overwhelmed
N=639 (15%)

Level 2:
becoming aware
N=561 (13%)

Level 3:
taking action
N=946 (22%)

Level 4: maintaining
behaviors
N=2,193 (51%)

66.9
33.1

73.9
26.1

72.0
28.0

62.2
37.8

,0.0001

65.8
34.2

61.6
38.4

59.9
40.1

58.3
41.7

0.0007

Emergency department visits
for COPD in past 12 months
None
$1

76.9
23.1

78.3
21.7

80.4
19.6

73.2
26.8

0.007

Hospital admissions for COPD in past
12 months
None
$1

80.2
19.8

85.9
14.1

87.0
13.0

84.7
15.3

0.053

55.5
44.5

55.0
45.0

55.6
44.4

58.0
42.0

0.143

25.4

33.6

41.3

66.3

,0.0001#

19.8

25.6

34.9

65.9

,0.0001#

17.4

18.5

26.8

56.6

,0.0001#

Number of comorbidities
0–1
$2
Number of COPD medications
0–1
$2

Education level
Elementary school
Higher education/technical college
or further education
Satisfaction with doctors management
of COPD
Very satisfied
Involved in decisions about treatment
Strongly agree
Treatment plan or goals set up
Strongly agree

Notes: ^Presented as column weighted percent unless otherwise stated; ¥tested across PAM-13 levels using weighted chi-square test, proportional odds model or weighted
ANOVA; #P-value derived across all response categories.
Abbreviations: SD, standard deviation; CAT, COPD Assessment Test; mMRC, modified Medical Research Council.

Univariate analysis showed that patients with low
PAM-13 scores were more often male, had lower BMI,
reported worse COPD-specific health status (higher CAT
score), worse breathlessness on exertion (mMRC $2), were
less likely to have undergone a past spirometry test, and
reported taking fewer COPD medications (Table 1). Patients
with low PAM-13 scores were also more likely to report
that they were “somewhat or very dissatisfied” with how
their physician manages their disease (P,0.001) (Figure 1;
Table 1) and were less likely to report being involved in
treatment decisions/having a disease management plan
(P,0.001) (Table 1). In the multivariate model (using characteristics showing a significant univariate relationship with
each respective outcome and including country), independent
factors associated with low levels of engagement (PAM-13
Levels 1 and 2) included increased breathlessness (mMRC
score $1), lower patient satisfaction with their doctor, low
BMI (,18.5 kg/m2; underweight), and poorer COPD-specific
health status (higher CAT score) (Table 2).
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Patient reported adherence with COPD
treatment and its determinants
Patient adherence results were based on 3,135 (72%) of
respondents who reported taking medication in the past
14 days and had completed the MMAS-8. Low MMAS-8
scores (poor adherence) were reported by 39% of patients,
with 35% reporting medium and 27% high adherence
(Table 3).
Patients with low MMAS-8 score were younger, more
often females, reported poorer COPD-specific health status
(higher CAT scores), were less likely to have undergone a
past spirometry test, and were slightly more likely to have
attended an emergency department in the previous 12 months
(Table 3). Patients reporting low or medium adherence more
often reported having $2 comorbidities compared with those
reporting high adherence. Poor adherers were also more
likely to report that they were “somewhat or very dissatisfied” with how their doctors manage their COPD (P,0.001)
(Figure 2; Table 3) and were less likely to report being
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Figure 1 Satisfaction of patients with their treating physicians stratified by Patient
Activation Measure (PAM)-13 level.
Note: Respondent % based on PAM level, that is, sum of proportions within each
PAM level add up to 100%.

involved in treatment decisions/having a disease management
plan (both P,0.001) (Table 3). In the multivariate analysis,
independent predictors of low treatment adherence included
younger patients, current smokers, less satisfaction with their
Table 2 Factors associated with low disease activation among
respondents with COPD (Patient Activation Measure Level 1
and 2)
Effect
Age (years)
40–59
Age $60
Sex
Female
Male
Smoking status
Former smoker
Current
Never
BMI (kg/m2)
,18.5
18.5–24.9
25–29.9
.30
mMRC grade
0
1
2
3
4

Odds ratio point
estimate (95% Wald CL)
1.11 (0.89–1.38)
Ref
1.17 (0.95–1.46)
Ref
0.95 (0.73–1.22)
Ref
1.19 (0.91–1.54)
1.77 (1.01–3.09)*
Ref
1.16 (0.91–1.47)
0.98 (0.74–1.30)
Ref
1.35 (1.01–1.82)*
1.72 (1.25–2.36)*
2.16 (1.47–3.19)*
1.87 (1.07–3.27)*

(Continued)
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Table 2 (Continued)
Effect

Odds ratio point
estimate (95% Wald CL)

Emergency department visits for
COPD, prior year
None
$1
Satisfaction with doctors
Very satisfied
Somewhat satisfied
Somewhat/very dissatisfied
CAT score
Per 2-unit increment
Self-reported history of past
spirometry
Yes
No
Number of comorbidities
0–1
$2
Number of COPD medications
0–1
$2

Ref
1.21 (0.93–1.57)
Ref
3.52 (2.5–6.83)*
2.12 (1.69–2.67)*
1.05 (1.02–1.08)*

0.83 (0.65–1.05)
Ref
Ref
0.97 (0.77–1.22)
Ref
0.83 (0.67–1.02)

Notes: The multivariate model was further adjusted for individual country. *This
variable remained statistically significant in the multivariate model (95% CL does not
include 1, P,0.05).
Abbreviations: CAT, COPD Assessment Test; CL, confidence limits; mMRC,
modified Medical Research Council; Ref, reference stratum.

doctor’s care, and $2 comorbidities, but not COPD-specific
health status or emergency department visits (Table 4).

Discussion
In our analysis of the Continuing to Confront COPD International Patient Survey, we report the first data on patient
engagement in a large sample of respondents fulfilling the
study definition of COPD. We observed that almost a third
(28%) of respondents struggled to understand their COPD
and were not actively engaged in the management of their
disease as indicated by low PAM-13 scores. Further, a large
number of respondents (39%) reported poor adherence with
COPD medications as indicated by low MMAS-8 scores.
COPD patient disengagement and lack of adherence to COPD
medications were associated with greater symptom burden
and poorer satisfaction with health care providers.
In a survey of a representative general population sample
of almost 18,000 adult residents of the US, 41% of respondents reported the highest level of engagement,19 comparable with our estimate of 50% of respondents reporting the
highest level of engagement. However, in our survey, more
than twice as many patients reported the lowest level of
engagement (15% vs 7%). Low engagement has also been
reported to be highly prevalent among patients with other
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Table 3 Characteristics of respondents with COPD according to adherence levels as measured with the Morisky Medication Adherence
Scale (MMAS)-8
International Journal of Chronic Obstructive Pulmonary Disease downloaded from https://www.dovepress.com/ by 128.163.8.74 on 18-Oct-2017
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Characteristic^

Females
Males
Age (years)
40–59
60+
Smoking status
Never smoker
Former smoker
Current smoker
BMI (kg/m2), mean (SD)
CAT score, weighted mean (SD)
CAT impact category
Low impact (1–10)
Medium impact (11–20)
High impact (21–30)
Very high impact (31–40)
mMRC dyspnea score
0–1
2–4
Self-reported history of past spirometry
Yes
No
Number of comorbidities
0–1
$2
Number of COPD medications
0–1
$2
Emergency department visits for COPD in past
12 months
None
$1
Hospital admissions for COPD in past 12 months
None
$1
Satisfaction with doctors management of COPD
Very satisfied
Involved in decisions about treatment
Strongly agree
Treatment plan or goals set up
Strongly agree
Education level
Elementary school
Higher education/technical college or further education

MMAS-8 scale

P-value across
MMAS-8 levels¥

Low adherence
(,6) N=1,065

Medium adherence
(6 to ,8) N=1,096

High adherence
(8) N=974

53.7
46.3

53.6
46.4

47.6
52.4

0.011

56.0
44.0

41.5
58.5

34.9
65.1

,0.001

35.2
34.6
30.2
27.2 (6.7)
23.6 (9.2)

36.6
43.9
19.8
27.1 (6.9)
23.2 (8.9)

31.3
45.3
23.5
26.7 (5.6)
21.4 (8.6)

0.254

9.0
24.0
43.5
23.6

10.9
25.5
41.4
22.3

14.9
28.8
38.9
17.3

,0.001

48.1
51.9

48.1
51.9

46.7
53.3

0.569

79.7
20.3

83.7
16.3

84.0
16.0

0.012

61.5
38.5

61.4
38.6

66.6
33.4

0.031

52.6
47.4

49.4
50.6

48.5
51.5

0.061

68.5
31.5

69.3
30.7

76.6
23.4

,0.001

80.9
19.1

78.6
21.4

83.1
16.9

0.314

44.7

54.9

63.8

,0.0001#

43.2

49.2

60.4

,0.0001#

38.5

42.3

53.0

,0.0001#

54.8
45.2

61.0
39.0

57.7
42.3

0.134

0.258
,0.001

Notes: ^Presented as column weighted percent unless otherwise stated; ¥tested across MMAS-8 levels using weighted chi-square test, proportional odds model or weighted
ANOVA; #P-value derived across all response categories.
Abbreviations: SD, standard deviation; CAT, COPD Assessment Test; mMRC, modified Medical Research Council.

chronic debilitating diseases;20–23 however, we identified
only one other study reporting data on patient engagement
in COPD.24 This study of 205 COPD patients, which focused
on retraining of health behaviors, showed a mean PAM-13
score at baseline (59.0), which is lower than that reported in
our study (66.75).
886
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When considering medication adherence, it has been
reported that in developed countries, 50% of patients with
chronic disease do not take their medications as prescribed.25
This level of nonadherence has also been reported in COPD
patients receiving home nebulizer therapy.26,27 George et al28
used a self-administered questionnaire (the medication
International Journal of COPD 2016:11
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Figure 2 Satisfaction of patients with their treating physicians stratified by Morisky
Medication Adherence Scale (MMAS)-8.
Note: Respondent % based on MMAS-8 level, that is, sum of proportions within
each MMAS-8 level add up to 100%.

Table 4 Factors associated with low adherence (Morisky Medication
Adherence Scale score ,6) among respondents with COPD
Effect
Age (years)
40–59
Age $60
Sex
Female
Male
Smoking status
Former smoker
Current
Never
Emergency department visits
for COPD, prior year
None
$1
Satisfaction with doctors
Very satisfied
Somewhat satisfied
Somewhat/very dissatisfied
CAT score
Per 2-unit increment
Self-reported history of past spirometry
Yes
No
Number of comorbidities
0–1
$2

Odds ratio point
estimate (95% Wald CL)
1.88 (1.55–2.29)*
Ref
1.08 (0.88–1.32)
Ref
1.04 (0.82–1.32)
1.65 (1.27–2.14)*
Ref

Ref
1.01 (0.80–1.27)
Ref
1.25 (1.00–1.56)
2.71 (1.91–3.85)*
1.01 (0.98–1.03)
0.91 (0.69–1.18)
Ref
Ref
1.25 (1.01–1.55)*

Notes: The multivariate model was further adjusted for individual country. *This
variable remained statistically significant in the multivariate model (95% CL does not
include 1, P,0.05).
Abbreviations: CAT, COPD Assessment Test; CL, confidence limits.
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adherence report scale) to assess adherence in COPD patients
identified through respiratory support groups and from a
pulmonary rehabilitation database, and also reported a higher
prevalence of nonadherence (63%) than that reported in the
current survey. Another recently published study evaluating
the adherence of COPD patients in a clinical setting using the
MMAS-4 reported poor adherence among 29.5% of COPD
patients, an estimate comparable with our survey.12 These
examples illustrate the reported variability in the prevalence
of adherence to treatment in COPD when assessed using a
range of methods or instruments in differing populations.
Both of these traits, poor patient engagement and adherence, were related to low levels of satisfaction with COPD
management by health care professionals, poorer COPDspecific health status (CAT score), and potentially either more
severe or less well-controlled disease as indicated by more
frequent emergency department visits. In a multivariate model
environment, satisfaction with their doctors’ management of
COPD appeared as the major factor impacting both engagement and adherence. Patients satisfied with their doctors as
well as those feeling more actively involved in decisions about
their treatment reported higher engagement and adherence
scores. Consistent with this, George et al28 reported that the
amount of time doctors spent with patients was a key determinant of medication adherence. Several studies have highlighted
that establishing a good doctor–patient relationship is necessary for fostering patient engagement in the consultation.29,30
Additional factors independently associated with low
engagement were poorer COPD-specific health status
(CAT) and the level of reported breathlessness as measured
with mMRC. Breathlessness has been described as the
most troublesome symptom by patients with COPD and
is a leading cause of disability.31 While poor engagement
was associated with poor COPD-specific health status and
COPD symptoms (breathlessness) in multivariate modeling,
these relationships were not maintained with the medication
adherence outcome in multivariate modeling. Similarly, the
relationship between prior health care utilization for COPD
exacerbations (hospital/emergency department visits),
although related to both low engagement and poor adherence on univariate testing, was attenuated for both in the
multivariate model. Several factors could have contributed
to such observations: patients with high engagement level
could potentially represent a mixed population of patients
from the extremes of the disease, that is, those with a
low disease severity as well as those with severe dyspnea
and poor health status. This hypothesis will be addressed
in a further analysis. The potential lack of temporality
of self-reported prior emergency department visits and
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hospitalizations for COPD and PAM-13 and MMAS-8
assessments limits the ability to study any mutual relationships. Further, health care utilization patterns significantly
differ across regions and the three geographical areas of
Asia, South America, and US/Europe represented in this
survey may have introduced heterogeneity. We also found
a relationship between BMI (underweight, overweight, and
obese) and low patient engagement. Such a relationship was
described by Fowles et al in a cohort of US employees.32
In their analysis, lower BMI predicted higher activation.
We have treated BMI as a nonlinear variable, based on our
a priori knowledge of an association of BMI with patient
reported outcomes in COPD;33 hence, we have shown that
being underweight, often associated with poorer outcomes
in COPD, is also related to poorer activation.
Other factors that were independent predictors of poor
adherence were current smokers, younger age (,65 years),
and presence of $2 comorbidities. A cross-sectional survey
of employees from a large US company, using a medical and
pharmacy claims database, also showed for a range of chronic
conditions that smokers were significantly less adherent to
medications than nonsmokers.34 Better adherence in older
patients with chronic diseases, including COPD, has been
shown in other studies.11,35 Further, others have reported on
an association between increased number of comorbidities
and poorer adherence.11 This is an important point for treating physicians. As the numbers of comorbidities increase,
so too typically do the number of medications prescribed to
a patient. Our data suggest these represent “at risk patients”
and in particular those who are poorly engaged may be even
more likely to be nonadherent to complex and frequently
expensive drug regimens.
Improved patient engagement may be expected to
translate into better control of disease and result in lower
disease burden. However, the Continuing to Confront COPD
International Patient Survey provides cross-sectional data so
we cannot infer the impact of these findings on long-term
outcomes in COPD patients. In the area of management
of diabetes, patient engagement interventions resulted in
modest improvements in intermediate outcomes, such as
hemoglobin A1c, but the evidence supporting clinically
important outcomes was considered as weak.36 One study
in COPD assessed the impact of repeated training sessions
on patient engagement, disease symptom burden, and
health-related quality of life.24 Although the intervention
significantly improved the level of engagement, disease burden and health-related quality of life remained unchanged,
highlighting the need for additional research. For patients,
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this may involve managing their COPD more effectively or
could also be a case of better management of their comorbidities, which may also result in better overall health and
outcomes.37 However, at the highest level of engagement,
patients may still struggle to maintain healthy behaviors
but report having the skills and confidence to manage their
health more proactively, which may in turn reduce the effect
of any intervention.19
A limitation of our results and their interpretation is
that the survey sampling method recruited patients from
the general population which may have resulted in a patient
group reporting milder disease than that usually observed
in a health care setting. A quarter of patients had not taken
any medications for COPD in the 2 weeks prior to the survey which may reflect a milder population but which could
also have been related to cultural variation in access to
medication. In addition, selection bias is another potential
limitation of this type of population-based survey. While a
large international span across three continents increased
the representativeness of the results, it is also likely to have
introduced heterogeneity with respect to cultural aspects
of expected patient and health care provider roles, and differences in access to health care. In addition, we assessed
disease burden using only a limited number of measures,
mainly patient self-reported outcomes. Approximately 80%
of the population self-reported that they had undergone a past
spirometry test but confirmation of spirometric diagnosis of
COPD by a review of patient records was not within the scope
of this survey. Although a third of our patient population
reported that they had never smoked, which is traditionally
atypical of a diagnosed COPD population, a review by Zeng
et al38 also reported the high burden of COPD in nonsmokers,
highlighting the variation in its prevalence across regions.
The frequency of nonsmokers in this study is still higher
than in any study in the review by Zeng et al in Western
countries (around 23%), but relatively comparable to the US
National Health and Nutrition Examination Surveys (~32%
for patients with spirometry results suggestive of airway
obstruction).38,39 Finally, despite collecting extensive data
on patient characteristics, we cannot rule out the fact that
unmeasured and important confounding factors may have
accrued and impacted our findings.

Conclusion
About a third of patients with COPD sampled from the
general population do not feel engaged or involved with
their COPD management and often report nonadherence
with treatment. COPD patients reporting disengagement and

International Journal of COPD 2016:11

International Journal of Chronic Obstructive Pulmonary Disease downloaded from https://www.dovepress.com/ by 128.163.8.74 on 18-Oct-2017
For personal use only.

Dovepress

lack of adherence to COPD medications also report greater
symptom burden and less satisfaction with their COPD
management. Further research is needed to identify how best
to help these patients and whether psychosocial, cultural, and/
or biological factors are driving these associations.
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